1. Barrett-Connor, E. and Khaw, K.T. (1990). The epidemiology of DHEA-S with particular reference to cardiovascular disease: The Rancho Bernardo study. In M. Kalimi & W. Regelson (Eds.),The Biologic Role of Dehydroepiandrosterone (DHEA). Berlin, New York: Walter de Gruyter, 281–298.
2. Barrett-Connor, E.; Khaw, K.T.; Yen, S.S. (1986). A prospective study of dehydroepiandrosterone (DHEA) sulfate, mortality, and cardiovascular disease.New England Journal of Medicine, 315(24): 1519–24.
3. Bernton, E.; Hoover, D.; Fein, H.; Galloway, R.; Smallridge, R. (1995). Abstract: Adaptation to chronic stress in military trainees: Adrenal androgens, testosterone, glucocorticoids, IGF-1 and immune function. Presented at The New York Academy of Sciences’ meeting on dehydroepiandrosterone (DHEA) and aging, Washington, D.C.
4. Bhatavdekar, J.M.; Patel, D.D.; Chikhlikar, P.R.; Mahta, R.H.; Vora, H.H.; Karelia, N.H.; Ghosh, N.; Shah, N.G.; Suthar, T.P.; Neema, J.P. (1994). Levels of circulating peptide and steroid hormones in men with lung cancer.Neoplasma, 41(2): 101–3.
5. Bhatavdekar, J.M.; Patel, D.D.; Shah, N.G.; Giri, D.D.; Vora, H.H.; Karelia, N.H.; Trivedi, S.N.; Ghosh, N.; Suthar, T.P. (1992). Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients.Neoplasma, 39(1): 39–42.